Steroid hormones and risk of breast cancer

Cancer

Volumn 74, Issue 3 S, 1994, Pages 1111-1124

  Hulka, Barbara S ^a   Liu, Edison T ^a   Lininger, Ruth A ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

biomarkers; breast cancer; epidemiology; steroid hormones

Indexed keywords

STEROID HORMONE; TUMOR MARKER;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CELL PROLIFERATION; CONFERENCE PAPER; GENE AMPLIFICATION; HORMONE METABOLISM; HORMONE SUBSTITUTION; HUMAN; MENARCHE; MENOPAUSE; PATHOGENESIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STEROID THERAPY;

BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMAN; MIDDLE AGE; PROGESTERONE; RECEPTORS, CELL SURFACE; RISK FACTORS;

EID: 0028132860     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19940801)74:3+<1111::AID-CNCR2820741520>3.0.CO;2-L     Document Type: Article

References (119)

1. Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma
2. Regulation of proliferation, invasion and growth factor synthesis in breast cancer by steroids
3. Cancer statistics, 1993
4. The relationship of cancer of the female breast to artificial menopause and marital status
5. The epidemiology of breast cancer
6. Hysterectomy, tubal sterilization, and the risk of breast cancer
7. Do regular ovulatory cycles increase breast cancer risk?
8. Early menarche, a risk factor for breast cancer, indicates early onset of ovulatory cycles
9. Menstrual cycle patterns and breast cancer risk factors
10. Combined effect of childbearing, menstrual events, and body size on agespecific breast cancer risk
11. Differentiation of the mammary gland and susceptibility to carcinogenesis
12. The epidemiology of serum sex hormones in postmenopausal women
13. Menopause and breast cancer risk
14. Increased risk of breast cancer with alcohol consumption in postmenopausal women
15. Projected changes in breast cancer incidence due to the trend toward delayed childbearing
16. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women
17. Oral contraceptives and breast cancer
18. A meta‐analysis of the effect of estrogen replacement therapy on the risk of breast cancer
19. Exogenous hormones and breast cancer
20. Hormones and proliferative activity in breast tissue
21. Behavioral antecedents and consequences of the menopause
22. Prescribing of noncontraceptive estrogens and progestins in the United States, 1974‐1986
23. Menopausal hormone replacement therapy and breast cancer: a meta‐analysis
24. Menopausal estrogen replacement therapy and breast cancer
25. Age‐specific differences in the relationship between oral contraceptive use and breast cancer
26. Oral contraceptives and breast cancer in young women
27. Oral contraceptive use and breast cancer in young women: a joint national case‐control study in Sweden and Norway
28. Breast cancer risk in relation to early oral contraceptive use
29. Early oral contraceptive use and breast cancer: results of another case‐control study
30. Oral contraceptives and breast cancer
31. Breast cancer and combined oral contraceptives: an Italian case‐control study
32. Early oral contraceptive use and breast cancer among premenopausal women: final report from a study in southern Sweden
33. Prospective study of oral contraceptive use and risk of breast cancer in women
34. Oral contraceptive use and breast cancer risk in young women
35. Oral contraceptives and breast cancer: latest findings in a large cohort study
36. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Breast cancer and combined oral contraceptives: results from a multinational study
37. Oral contraceptives and risk of breast cancer
38. Breast cancer risk and oral contraceptive use : results from a large case‐control study
39. Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age of use
40. Menopausal oestrogens and breast cancer risk: an expanded case‐control study
41. Menopausal estrogens use and the risk of breast cancer
42. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy
43. Prospective study of exogenous hormone use and breast cancer in Seventh‐Day Adventists
44. Estrogen replacement therapy and the risk of breast cancer: results from the case‐control surveillance study
45. Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study
46. Breast cancer risk: effects of estrogen replacement therapy and body mass
47. Hormone‐replacement therapy and the risk of breast cancer
48. Non‐contraceptive oestrogens and the risk of breast cancer in women
49. Long‐term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy
50. Influence of non‐contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark
51. The risk of breast cancer after estrogen and estrogen‐progestin replacement
52. Oral contraceptives in the United States: trends in content and potency
53. Methodological issues in epidemiologic studies using biologic markers
54. Sex hormone levels in serum in relation to the development of breast cancer
55. Sex hormones and postmenopausal breast cancer: a prospective study in an adult community
56. Benign and malignant breast disease: initial study results of serum and breast fluid analyses of endogenous estrogens
57. Distribution of estradiol and percentage of free testosterone in sera of Japanese women: preoperative breast cancer patients and normal controls
58. Endogenous sex hormones, prolactin, and breast cancer in premenopausal women
59. Urine estrogens, frequency of ovulation, and breast cancer risk: case‐control study in premenopausal women
60. Low urinary estrogen glucuronides in women at risk for familial breast cancer
61. Plasma hormone profiles of young women at risk for familial breast cancer
62. Studies on the epidemiology and natural history of benign breast disease and breast cancer using nipple aspirate fluid
63. Subcellular concentrations of estrone, estradiol and androstenedione and 17β‐hydroxysteroid dehydrogenase (17β‐OH‐SDH) activity in malignant and non‐malignant human breast tissues
64. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue
65. Metabolism of [3H]oestradiol in vivo by normal breast and tumor tissue in postmenopausal women
66. Anitestrogen action of progesterone in breast tissue
67. Increased Estrogen‐16α‐hydroxylase activity in women with breast and endometrial cancer
68. Increased 2‐hydroxylation of estradiol as a possible mechanism for the anti‐estrogenic effect of cigarette smoking
69. Estrogen receptor expression in human breast cancer associated with estrogen receptor gene restriction fragment length polymorphism
70. Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle
71. Estrogen and progesterone receptors in the normal female breast
72. Estrogen receptor in dissociated and cultured human breast fibroadenoma epithelial cells
73. Estrogen and progesterone receptors in benign breast tumors and lesions; relationship with histological and cytological features
74. Androgen, estrogen and progesterone receptor levels in malignant and benign breast tumors: a multivariate analysis approach
75. The correlation of cytologic grade and steroid receptor content in effusions of metastatic breast carcinoma
76. Estradiol and progesterone receptor levels in human breast cancer in relation to cytosol and plasma estrogen level
77. Activated oestrogen receptor in human breast cancer: clinical and biochemical correlates
78. Structure and function of the estrogen receptor and other members of the nuclear receptor family
79. Epidermal growth factor gene expression in human breast cancer biopsy samples: relationship to estrogen and progesterone receptor gene expression
80. Regulation of human estrogen receptor gene, epidermal growth factor receptor gene and oncogenes by estrogen and antiestrogen in MCF‐7 breast cancer cells
81. Estrogen receptors and breast cancer
82. Hormonal and personal effects on estrogen receptors in breast cancer
83. Differences in breast cancer risk factors according to the estrogen receptor level of the tumor
84. HER‐2/ neu and int‐2 proto‐oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones
85. A case‐control study of breast cancer stratified by estrogen receptor status
86. Oral contraceptive use influences resting breast proliferation
87. The effect of age and menstrual cycle upon proliferative activity of the normal human breast
88. Cell turnover in the “resting” human breast: influence of parity, contraceptive pill, age and laterality
89. Growth factor expression in breast tissue
90. Over‐expression of either c‐myc or c‐erbB‐2/neu proto‐oncogenes in human breast carcinomas: correlation with poor prognosis
91. Isolation of the neu/HER‐2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells
92. Identification of heregulin, a specific activator of p185erbB2
93. Studies of the HER‐2/neu proto‐oncogene in human breast and ovarian cancer
94. Correlation between long‐term survival in breast cancer patients and amplification of two putative oncogene‐coamplification units: hst‐I/int‐2 and c‐erbB‐2/ear‐1
95. Differences in breast cancer risk factors to neu (c‐erbB‐2) protein overexpression of the breast tumor
96. The putative oncogene PRADI encodes a novel cyclin
97. Association of int2/HST1 coamplification in primary breast cancer with hormone‐dependent phenotype and poor prognosis
98. Amplification of the int‐2 gene in primary human breast tumors
99. p53 mutations in human cancers
100. Closing in on a breast cancer gene on chromosome 17q
101. HRAS protooncogene polymorphism and breast cancer
102. Human hypervariable sequences in risk assessment: rare ha‐ras alleles in cancer patients
103. Abnormal estrogen receptor in clinical breast cancer
104. Oestrogen receptor B‐region polymorphism and spontaneous abortion in women with breast cancer
105. B region variant of the estrogen receptor gene
106. Incidence of an estrogen receptor polymorphism in breast cancer patients
107. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors
108. Hormonal regulation of synthesis and secretions of pS2 protein relevant to growth of human breast cancer cells (MCF‐7)
109. Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF‐7
110. Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene erbB2